Presentations – 17th European Meeting on HIV & Hepatitis

Wednesday 22 MayThursday 23 MayFriday 24 May

Day 1 - Wednesday, 22 May


Andrea De Luca Lecture:

The top 10 important observations of the last year affecting clinical management
Ravindra Gupta, MD, PhD
University of Cambridge, United Kingdom


Resistance to integrase inhibitors
(Not yet available)
Anne-Genevieve Marcelin, PharmD, PhD
UPMC, France

 Session 1: The role of the reservoir on clinical decision making
Chairs: Rolf Kaiser and Jan Albert

How to measure the reservoir
(No permission to publish)

María José Buzón, PhD
Vall d'Hebron Research Institute, Spain

 How does the reservoir influence the clinician's decisions

Carlo Federico Perno, MD, PhD
University of Milan, Italy

 Special Session: Genetic Barrier – Role in HIV Treatment Decisions
Chair: Charles Boucher

Jonathan Schapiro, MDGenetic Barrier, Basic Principles
(No permission to publish)
Jonathan Schapiro, MD
Sheba Medical Centre, Israel


Romina P. Quercia, MD, PhDGenetic Barrier and Reduced Drug Regimens
(Not yet available)
Romina Quercia, MD, PhD
ViiV Healthcare, United Kingdom


Roger Paredes, MD, PhD Genetic Barrier – Clinical Cases

Roger Paredes, MD, PhD
IrsiCaixa AIDS Research Institute, Spain

 Session 2: Role of STI management in HIV prevention
Chairs: Gary Rubin and David van de Vijver
 Whitlock, Gary 2019New approaches to STI management
Gary Whitlock, MD
Dean Street Clinic, Chelsea & Westminster Hospital
United Kingdom
 Bébéar, Cecile 2019 120x160Interplay between PrEP and STI
(No permission to publish)

Cécile Bébéar, MD, PhD
University of Bordeaux, France
 Abstract - driven presentations
 First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain.
Manuel Reiriz Rojas
 European surveillance of HIV drug resistance to NRTI, NNRTI and INSTI in newly diagnosed individuals using next-generation sequencing.
Carole Seguin-Devaux
 Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France.
Evangelia Kostaki
 Trends of transmitted and acquired hiv-1 drug resistance in patients followed in portuguese hospitals between 2001 and 2017.
(Not yet available)

Marta Pingarilho
 Session 3: Clinical management of HIV - related abstracts
Chairs: Roger Paredes and Anne- Mieke Vandamme
 Remembering Ricardo Camacho: HIV-2 Diagnostics, therapy and resistance testing
(Not yet available)

Rolf Kaiser, PhD
University of Cologne, Germany

 Abstract-driven presentations
 Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)
Charlotte Charpentier
 Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study
Barbara Rossetti
 High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation
Alina Kirichenko
 Fostemsavir (FTR) Week 48 efficacy and evaluation of treatment emergent substitutions in the BRIGHTE study
(Not yet available)

Max Lataillade
 Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Anne- Geneviéve Marcelin

Day 2 - Thursday, 23 May

 Session 4: What's in the pipeline? Presentations from scientists from the industry
Chair: Jonathan Schapiro and Anne-Geneviève Marcelin
 Harmony Garges 120x160Harmony P. Garges, MD,  MPH
(No permission to publish)

Vice President and Head, Global Medical Affairs, ViiV Healthcare, USA
 Stamm, Luisa 120x160Luisa Stamm, MD, PhD
Executive Director, HIV and Emerging Viral Infections, Gilead Sciences, USA
 Squires, Kathleen 2012Kathleen Squires, MD
(Not yet available)

Global Director Scientific Affairs-ID/HIV, Merck, USA
 Hanneke Schuitemaker, PhD
(Not yet available)

Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen, The Netherlands
 Special Session: Clinical considerations in choosing first-line therapy
Chair: Carlo Federico Perno

Carlo Federico Perno, MD, PhDWelcome and introduction
(No permission to publish)
Carlo Federico Perno, MD, PhD
University of Milan, Italy


Same day treatment initiation
(No permission to publish)

Tristan Barber, MA MRCP
Royal Free Hospital, London, United Kingdom


Anne-Geneviève Marcelin, PharmD, PhDFirst line therapies: implications for long term resistance

Anne- Geneviève Marcelin, PharmD, PhD
Pierre et Marie Curie University, Paris, France

 Clinical case
Rocio Montejano Sanchez, MD
Hospital Universitario La Paz, Madrid, Spain
  Session 5: Management of viral hepatitis I
Chairs: Francesca Ceccherini Silberstein and Carlo Perno

Novel compounds for HBV therapy
(No permission to publish)
Pietro Lampertico, MD, PhD
Fondazione Policlinico - University of Milan, Italy


Novel markers on HBV / HDV co-infection

Valentina Svicher, PhD
University of Rome Tor Vergata, Italy

 Abstract-driven presentations
 The integration of Hepatitis B virus in relevant regions of human genome is a common event in the setting of HBeAg negative chronic infection despite limited liver disease: implications for an altered cell metabolism
(No permission to publish)

Romina Salpini
 The transmission dynamics of acute HCV infections in HIV-positive men who have sex with men in the Netherlands is suitable for targeted risk reduction strategies
(Not yet available)

Stephanie Popping (Presented by David van de Vijver)
 Session 6: Management of viral hepatitis II
Chair: t.b.c.

Clinical relevance of HCV rare subtypes
(Not yet available)

Slim Fourati, MD, PhD
University of Paris Est, France

 Abstract-driven presentations
 Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Glecaprevir and Pibrentasvir (G/P) treatment in real world
(No permission to publish)

Federico Garcia
 Retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen after performing a genotypic resistance test: the Italian Vironet C real life experience
(No permission to publish)

Velia Chiara Di Maio
 Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b
Mohammad Altkhatib

Day 3 - Friday, 24 May

 Session 7: Clinical management challenges
Chair: t.b.c.

The new patient - with what & when

Peter Reiss, MD, PhD
UMC Amsterdam, The Netherlands


The aging patient

Eugenia Negredo, PhD
Hospital Universitari Germans Trias i Pujol, Badalona, Spain


Mandelbrot, Laurent 2017 120x160The pregnant woman - update
(Not yet available)

Laurent Mandelbrot, MD
Hôpitaux Universitaires Paris Nord, Paris, France

 Session 8: Abstracts - part I
Chair:  Leon Kostrikis
 Longitudinal analysis of proviral HIV-DNA
Eva Heger
 Single genome sequencing of near full-length HIV-1 RNA
Laura Hebberecht
 Session 9: Abstracts - part II
Chair: t.b.c.
 Maraviroc as a Latency Reversing Agent in cell line models
Filippo Dragoni
 Viral Dynamics During Suppressive ART - Towards HIV-1 Elimination From Reservoirs
(Not yet available)

Thomas Klimkait
 Session 10: Progress in cure / elimination approaches
Chairs: Dimitrios Paraskevis and Carlo Perno

Update on the London patient

Ravindra Gupta, MD, PhD
University of Cambridge, United Kingdom


Update on HIV cure research
(No permission to publish)
Linos Vandekerckhove, MD, PhD 
University of Gent, Belgium


Perspectives in HBV cure research

Fabien Zoulim, MD
INSERM, France